BIRC5 and cancer: Along the same vein, either GRP78 or Survivin silencing could sensitize Mahlavu cells to be effectively eradicated by a group of ROS-producing anti-cancer drugs including sorafenib, 5-FU, paclitaxel and doxorubicin (Figure 7).